Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2017

Open Access 01-12-2017 | Research

Human germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis

Authors: Vicente Planells-Palop, Ali Hazazi, Julia Feichtinger, Jana Jezkova, Gerhard Thallinger, Naif O. Alsiwiehri, Mikhlid Almutairi, Lee Parry, Jane A. Wakeman, Ramsay J. McFarlane

Published in: Molecular Cancer | Issue 1/2017

Login to get access

Abstract

Background

Cancer/testis (CT) genes have expression normally restricted to the testis, but become activated during oncogenesis, so they have excellent potential as cancer-specific biomarkers. Evidence is starting to emerge to indicate that they also provide function(s) in the oncogenic programme. Human TEX19 is a recently identified CT gene, but a functional role for TEX19 in cancer has not yet been defined.

Methods

siRNA was used to deplete TEX19 levels in various cancer cell lines. This was extended using shRNA to deplete TEX19 in vivo. Western blotting, fluorescence activated cell sorting and immunofluorescence were used to study the effect of TEX19 depletion in cancer cells and to localize TEX19 in normal testis and cancer cells/tissues. RT-qPCR and RNA sequencing were employed to determine the changes to the transcriptome of cancer cells depleted for TEX19 and Kaplan-Meier plots were generated to explore the relationship between TEX19 expression and prognosis for a range of cancer types.

Results

Depletion of TEX19 levels in a range of cancer cell lines in vitro and in vivo restricts cellular proliferation/self-renewal/reduces tumour volume, indicating TEX19 is required for cancer cell proliferative/self-renewal potential. Analysis of cells depleted for TEX19 indicates they enter a quiescent-like state and have subtle defects in S-phase progression. TEX19 is present in both the nucleus and cytoplasm in both cancerous cells and normal testis. In cancer cells, localization switches in a context-dependent fashion. Transcriptome analysis of TEX19 depleted cells reveals altered transcript levels of a number of cancer-/proliferation-associated genes, suggesting that TEX19 could control oncogenic proliferation via a transcript/transcription regulation pathway. Finally, overall survival analysis of high verses low TEX19 expressing tumours indicates that TEX19 expression is linked to prognostic outcomes in different tumour types.

Conclusions

TEX19 is required to drive cell proliferation in a range of cancer cell types, possibly mediated via an oncogenic transcript regulation mechanism. TEX19 expression is linked to a poor prognosis for some cancers and collectively these findings indicate that not only can TEX19 expression serve as a novel cancer biomarker, but may also offer a cancer-specific therapeutic target with broad spectrum potential.
Appendix
Available only for authorised users
Literature
1.
Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol. 2016;11:47–76.CrossRefPubMed
2.
3.
Feichtinger J, Larcombe L, McFarlane RJ. Meta-analysis of expression of l(3)mbt tumor-associated germline genes supports the model that a soma-to-germline transition is a hallmark of human cancers. Int J Cancer. 2014;134:2359–65.CrossRefPubMed
4.
Koslowski M, Bell C, Seitz G, Lehr HA, Roemer K, Müntefering H, Huber C, Sahin U, Türeci O. Frequent nonrandom activation of germ-line genes in human cancer. Cancer Res. 2004;64:5988–93.CrossRefPubMed
5.
6.
Nielsen AY, Gjerstorff MF. Ectopic expression of testis germ cell proteins in cancer and its potential role in genomic instability. Int J Mol Sci. 2016;17(6). doi:10.​3390/​ijms17060890.
7.
Janic A, Mendizabal L, Llamazares S, Rossell D, Gonzalez C. Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila. Science. 2010;330:1824–7.CrossRefPubMed
8.
Fagegaltier D, Falciatori I, Czech B, Castel S, Perrimon N, Simcox A, Hannon GJ. Oncogenic transformation of Drosophila somatic cells induces a functional piRNA pathway. Genes Dev. 2016;30:1623–35.CrossRefPubMedPubMedCentral
9.
Sumiyoshi T, Sato K, Yamamoto H, Iwasaki YW, Siomi H, Siomi MC. Loss of l(3)mbt leads to acquisition of the pin-pong cycle in Drosophila ovarian somatic cells. Genes Dev. 2016;30:1617–22.CrossRefPubMedPubMedCentral
10.
Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:615–25.CrossRefPubMed
11.
Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Nicolay HJ, Sigalotti L, Maio M. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011;5:164–82.CrossRefPubMed
12.
Whitehurst AW. Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol. 2014;54:251–71.CrossRefPubMed
13.
14.
Por E, Byun HJ, Lee EJ, Lim JH, Jung SY, Park I, Kim YM, Jeoung DI, Lee H. The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner. J Biol Chem. 2010;285:14475–85.CrossRefPubMedPubMedCentral
15.
Whitehurst AW, Xie Y, Purinton SC, Cappell KM, Swanik JT, Larson B, Girard L, Schorge JO, White MA. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res. 2010;70:7652–61.CrossRefPubMedPubMedCentral
16.
Cappell KM, Sinnot R, Taus P, Maxfield K, Scarbrough M, Whitehurst AW. Multiple cancer testis antigens function to support tumor cell mitotic fidelity. Mol Cell Biol. 2012;32:4131–40.CrossRefPubMedPubMedCentral
17.
D’Arcy P, Maruwge W, Wolaham B, Ma L, Brodin B. Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells. PLoS One. 2014;9:e95136.CrossRefPubMedPubMedCentral
18.
Maxfield KE, Taus PJ, Corcoran K, Wooten J, Macion J, Shou Y, Borromeo M, Kollipara RK, Yan J, Xie Y, Xie XJ, Whitehurst AW. Comprehensive functional characterization of cancer-testis antigens defines obligate participation in multiple hallmarks of cancer. Nat Commun. 2015;16:8840.CrossRef
19.
Greve KB, Lindgreen JN, Terp MG, Pedersen CB, Schmidt S, Mollenhauer J, Kristensen SB, Andersen RS, Relster MM, Ditzel HJ, Gjerstorff MF. Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. Mol Oncol. 2015;9:437–49.CrossRefPubMed
20.
Wang D, Wang J, Ding N, Li Y, Yang Y, Fang X, Zhao H. MAGE-A1 promotes melanoma proliferation and migration through c-JUN activation. Biochem Biophys Res Comm. 2016;473:959–65.CrossRefPubMed
21.
Caballero OL, Cohen T, Gurung S, Chua R, Lee P, Chen YT, Jat P, Simpson AJ. Effects of CT-Xp gene knock down in melanoma cell lines. Oncotarget. 2013;4:531–41.CrossRefPubMedPubMedCentral
22.
Yang F, Zhou X, Miao X, Zhang T, Hang X, Tie R, Liu N, Tian F, Wang F, Yuan J. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast Cancer Res Treat. 2014;145:23–32.CrossRefPubMedPubMedCentral
23.
Shang B, Gao A, Pan Y, Zhang G, Tu J, Zhou Y, Yang P, Cao Z, Wei Q, Ding Y, Zhang J, Zhao Y, Zhou Q. CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis. Cell Death Dis. 2014;5:e1285.CrossRefPubMedPubMedCentral
24.
Hsiao YJ, Su KY, Hsu YC, Chang GC, Chen JS, Chen HY, Hong QS, Hsu SC, Kang PH, Hsu CY, Ho BC, Yang TH, Wang CY, Jou YS, Yang PC, Yu SL. SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma. Oncotarget. 2016;doi:10.​18632/​Oncotarget.​10088.
25.
Maine EA, Westcott JM, Prechtl AM, Dang TT, Whitehurst AW, Pearson GW. The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion. Oncotarget. 2016;7:14708–26.PubMedPubMedCentral
26.
Feichtinger J, Aldeailej I, Anderson R, Almutairi M, Almatrafi A, Alsiwiehri N, Griffiths K, Stuart N, Wakeman JA, Larcombe L, McFarlane RJ. Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes. Oncotarget. 2012;3:843–53.CrossRefPubMedPubMedCentral
27.
Sammut SJ, Feichtinger J, Stuart N, Wakeman JA, Larcombe L, McFarlane RJ. A novel cohort of cancer-testis biomarker genes revealed through meta-analysis of clinical data sets. Oncoscience. 2014;1:349–59.CrossRefPubMedPubMedCentral
28.
Wang PJ, McCarrey JR, Yang F, Page DC. An abundance of X-linked genes expressed in spermatagonia. Nat Genet. 2001;27:422–6.CrossRefPubMed
29.
Kuntz S, Kieffer E, Bianchetti L, Lamoureux N, Fuhrmann G, Viville S. Tex19, a mammalian-specific protein with a restricted expression in pluripotent stem cells and germ line. Stem Cells. 2008;26:734–44.CrossRefPubMed
30.
Wang C, Gu Y, Zhang K, Xie K, Zhu M, Dai N, Jiang Y, Guo X, Liu M, Dai J, Wu L, Jin G, Ma H, Jiang T, Yin R, Xia Y, Liu L, Wang S, Shen B, Huo R, et al. Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. Nature Comm. 2015;7:10499.CrossRef
31.
Zhong J, Chen Y, Liao X, Li J, Wang H, Wu C, Zou X, Yang G, Shi J, Luo L, Liu L, Deng J, Tang A. Testis expressed 19 is a novel cancer-testis antigen expressed in bladder cancer. Tumour Biol. 2016;37:7757–65.CrossRefPubMed
32.
Hackett JA, Reddington JP, Nestor CE, Dunican DS, Branco MR, Reichmann J, Reik W, Surani MA, Adams IR, Meehan RR. Promoter DNA methylation couples genome-defense mechanisms to epigenetic reprogramming in the mouse germline. Development. 2012;139:3623–32.CrossRefPubMedPubMedCentral
33.
Tarabay Y, Kieffer E, Teletin M, Celebi C, Van Montfoort A, Zamudio N, Achour M, Ramy EI, Gazdag E, Tropel P, Mark M, Bourc’his D, Ville S. The mammalian-specific Tex19.1 gene plays an essential role in spermatogenesis and placenta-supported development. Human Rep. 2013;28:2201–14.CrossRef
34.
Öllinger R, Childs AJ, Burgess HM, Speed RM, Lundergaard PR, Reynolds N, Gray NK, Cooke HJ, Adams IR. Deletion of the pluripotency-associated Tex19.1 gene causes activation of endogenous retroviruses and defective spermatogenesis in mice. PLoS Genet. 2008;4:e1000199.CrossRefPubMedPubMedCentral
35.
Reichmann J, Reddington JP, Best D, Read D, Öllinger R, Meehan RR, Adams IR. The genome-defense gene Tex19.1 suppresses LINE-1 retrotransposons in the placenta and prevents intra-uterine growth retardation in mice. Hum Mol Genet. 2013;22:1791–806.CrossRefPubMedPubMedCentral
36.
Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, Laffaire J, de Reyniés A, Beer DG, Timsit JF, Brambilla C, Brambilla E, Knochbin S. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Trans Med. 2013;5:186ra66.CrossRef
37.
Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:70–8.CrossRefPubMed
38.
Jezkova J, Williams JS, Jones-Hutchinson F, Sammut SJ, Gollins S, Cree I, Coupland S, McFarlane RJ, Wakeman JA. Brachyury regulates proliferation of cancer cells via a p27Kip1-dependent pathway. Oncotarget. 2014;5:3813–22.CrossRefPubMedPubMedCentral
39.
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R4.CrossRef
40.
41.
42.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289–300.
43.
Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics. 2007;23:257–8.CrossRefPubMed
44.
45.
Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Huber W, Irizarry R, Dudoit S, editors. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York: Springer; 2005. p. 397–420.CrossRef
46.
Therneau TM, Grambsch PM. Modelling survival data: extending the Cox model. New York: Springer; 2000.CrossRef
47.
Neto FT, Bach PV, Najari BB, Li PS, Goldstein M. Spermatogenesis in humans and its affecting factors. Semin Cell Dev Biol. 2016;59:10–26.
48.
Jezkova J, Williams JS, Pinto F, Sammut SJ, Williams GT, Gollins S, McFarlane RJ, Reis RM, Wakeman JA. Brachyury identifies a class of enteroendocrine cells in normal human intestinal crypts and colorectal cancer. Oncotarget. 2016;7:11478–86.PubMedPubMedCentral
49.
Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501:338–45.CrossRefPubMed
50.
51.
52.
Chenias B. Transposable elements in cancer and other human diseases. Curr Cancer Drug Targets. 2015;15:227–42.CrossRef
53.
Jaendling A, McFarlane RJ. Biological roles of translin and translin-associated factor X: RNA metabolism comes to the fore. Biochem J. 2010;429:225–34.CrossRefPubMed
54.
Gomez-Escobar N, Almobadel N, Alzahrani O, Feichtinger J, Planells-Palop V, Alshehri Z, Thallinger GG, Wakeman JA, McFarlane RJ. Translin and Trax differentially regulate telomere-associated transcript homeostasis. Oncotarget. 2016; doi:10.​18632/​Oncotarget.​9278.
55.
Ishida R, Ohado H, Sato H, Shionoiri C, Aoki K, Kasai M. A role for the octomeric ring protein, Translin, in mitotic cell division. FEBS Lett. 2002;525:105–10.CrossRefPubMed
56.
Yang S, Cho YS, Chennathukuzhi VM, Underkoffler LA, Loomes K, Hecht NB. Translin-associated factor-X is post-transcriptionally regulated by its partner protein TB-RBP, and both are essential for normal cell proliferation. J Biol Chem. 2004;279:12605–14.CrossRefPubMed
57.
George OL, Ness SA. Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis. Cancers. 2014;6:2049–71.CrossRefPubMedPubMedCentral
58.
Vera-Badillo FE, Conde E, Duran I. Chromophobe renal cell carcinoma: a review of an uncommon entity. Int J Urol. 2012;19:894–900.CrossRefPubMed
59.
Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guillé F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Fiqlin RA, Belldegrun AS, Pantuck AJ. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–71.CrossRefPubMed
60.
Cho NW, Dilley RL, Lampson MA, Greenberg RA. Interchromosomal homology searches drive directional ALT telomere movement and synapsis. Cell. 2014;159:108–21.CrossRefPubMedPubMedCentral
61.
Gjerstorff MF, Relster MM, Greve KB, Moeller JB, Elias D, Lindgreen JN, Schmidt S, Mollenhauer J, Voldborg B, Pedersen CB, Brückmann NH, Møllegaard NE, Ditzel HJ. SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression. Nucleic Acids Res. 2014;42:11433–46.CrossRefPubMedPubMedCentral
62.
Ciró M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capara M, Christensen J, Helin K. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009;69:8491–8.CrossRefPubMed
63.
Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Bramilla C, Bramilla E, Rousseaux S, Knochbin S. Functional characterization of ATAD2 as a new cancer/testis factor and predictor of poor prognosis in breast and lung cancers. Oncogene. 2010;29:5171–81.CrossRefPubMed
64.
Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD, Chen HW. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010;70:9402–12.CrossRefPubMedPubMedCentral
65.
Boussouar F, Jamshidikia M, Morozumi Y, Rousseaux S, Khochbin S. Malignant genome reprogramming by ATAD2. Biochim Biophys Acta. 1829;2013:1010–4.
66.
Hwang HW, Ha SY, Bang H, Park CK. ATAD2 as a poor prognostic marker for hepatocellular carcinoma after curative resection. Cancer Res. 2015;47:853–61.
67.
Krakstad C, Tangen IL, Hoivik EA, Halle MK, Berg A, Werner HM, Raeder MB, Kusonmano K, Zou JX, Øyan AM, Stefansson I, Trovik J, Kalland KH, Chen HW, Salvesen HB. ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget. 2015;6:28440–52.CrossRefPubMedPubMedCentral
68.
Lu WJ, Chua MS, So SK. Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activity of p53- and p38-mediated apoptotic signaling. Oncotarget. 2015;6:41722–35.PubMedPubMedCentral
69.
Luo Y, Ye GY, Qin SL, Yu MH, Mu YF, Zhong M. ATAD2 overexpression identifies colorectal cancer patients with poor prognosis and drives proliferation of cancer cells. Gastroenterol Res Pract. 2015;2015:936564.PubMedPubMedCentral
70.
Zhang MJ, Zhang CZ, Du WJ, Yang XZ, Chen ZP. ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker. Clin Transl Oncol. 2015;18:776–81.CrossRefPubMed
71.
Zheng L, Li T, Zhang Y, Guo Y, Yao J, Dou L, Guo K. Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer. Oncol Rep. 2015;33:2337–44.PubMed
72.
Hou M, Huang R, Song Y, Feng D, Jiang Y, Liu M. ATAD2 overexpression is associated with progression and prognosis in colorectal cancer. Jpn J Clin Oncol. 2016;46:222–7.CrossRefPubMed
73.
Yang F, Cheng Y, An JY, Kwon YT, Eckardt S, Leu NA, McLaughlin KJ, Wang PJ. The ubiquitin ligase Ubr2, a recognition E3 component of the N-end rule pathway, stabilizes Tex19.1 during spermatogenesis. PLoS One. 2010;5:e14017.CrossRefPubMedPubMedCentral
74.
75.
Wansleben S, Peres J, Hare S, Goding CR, Prince S. T-box transcription factors in cancer biology. Biochim Biophys Acta. 1846;2014:380–91.
76.
Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L, Menei P, Quillien V, Mosser J. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics. 2010;11:701.CrossRefPubMedPubMedCentral
77.
Park JC, Chae YK, Son CH, Kim MS, Lee J, Ostrow K, Sidransky D, Hoque MO, Moon C. Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun. 2008;365:221–6.CrossRefPubMed
78.
Rodriguez M, Aladowicz E, Lanfrancone L, Goding CR. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res. 2008;68:7872–81.CrossRefPubMed
79.
Burgucu D, Guney K, Sahinturk D, Ozbudak IH, Ozel D, Ozbilim G, Yavuzer U. Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma. BMC Cancer. 2012;12:481.CrossRefPubMedPubMedCentral
80.
Richardson SR, Morell S, Faulkner GJ. L1 retrotransposons and somatic mosaicism in the brain. Ann Rev Genet. 2014;48:1–27.CrossRefPubMed
Metadata
Title
Human germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis
Authors
Vicente Planells-Palop
Ali Hazazi
Julia Feichtinger
Jana Jezkova
Gerhard Thallinger
Naif O. Alsiwiehri
Mikhlid Almutairi
Lee Parry
Jane A. Wakeman
Ramsay J. McFarlane
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2017
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-017-0653-4

Other articles of this Issue 1/2017

Molecular Cancer 1/2017 Go to the issue

Review

Nano-based delivery of RNAi in cancer therapy

Review

11q deletion in neuroblastoma: a review of biological and clinical implications

Research

Over-expressed long noncoding RNA HOXA11-AS promotes cell cycle progression and metastasis in gastric cancer

Review

Mesenchymal stem cells: key players in cancer progression

Review

Ovarian cancer stem cells: still an elusive entity?

Review

Neutrophils in cancer: prognostic role and therapeutic strategies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits